Loading, Please Wait...
BOSTON, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX) and certain of its officers and directors violated federal securities laws.
On February 28, 2019, it was revealed that Akorn received an FDA Form 483 from the Food and Drug Administration following an inspection of the Company’s Amityville, New York manufacturing facility. This inspection revealed that contrary to Akorn’s representations to shareholders, the Company had failed to comply with multiple federal regulations pertaining to drug manufacturing.
Last month, Akorn disclosed that it had received a warning letter from the Food and Drug Administration following an inspection of the Company’s Decatur, Illinois manufacturing facility. That inspection also revealed that contrary to Akorn’s representations to shareholders, the Company had failed to comply with multiple federal regulations pertaining to drug manufacturing.
If you have purchased or otherwise acquired Akorn securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney Dan DeMaria at (888) 868-2385, by email at email@example.com, or by visiting http://shareholder.law/akorn.
Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
BLOCK & LEVITON LLP
(617) 398-5660 phone
155 Federal Street, Suite 400
Boston, MA 02110
SOURCE Block & Leviton LLP